LIXTE BIOTECHNOLOGY COMMENTS ON REPORT THAT ITS PP2A INHIBITOR LB-100 COMBINED WITH ANOTHER INVESTIGATIONAL AGENT STIMULATES BONE GROWTH IN MODELS OF DWARFISM
22 Luglio 2021 - 3:25PM
Lixte Biotechnology Holdings, Inc. (Nasdaq:LIXTE) a clinical-stage
drug discovery company developing pharmacologically active drugs
for improving cancer treatments, commented on pre-clinical research
demonstrating that inhibition of protein phosphatase 2A (PP2A) with
LB-100 combined with the experimental drug, vosoritide (BioMarin),
was even more effective than vosorotide alone in stimulating bone
length and cartilage area in a mouse model of the most common form
of dwarfism, achondroplasia (ACH).
In clinical trials, the BioMarin compound alone
was beneficial. But the fact that the addition of LB-100 enhanced
the activity of vosoritide in the animal models of ACH led the
authors to conclude that their study provides a proof of concept
that a phosphatase inhibitor may be a beneficial addition to
therapy with vosoritide (Shuhaibar et al., JCI Insight 2021).
Lixte CEO, John S. Kovach MD, commented “Our
development of LB-100 as the only presently available PP2A
inhibitor in clinical trials has opened a multitude of
possibilities for adding inhibition of PP2A to therapeutic regimens
for a range of serious diseases. LB-100 has been shown to enhance
anti-cancer activity of standard chemotherapy and immunotherapy
regimens against a broad spectrum of human cancers in animal
models. Our focus is to demonstrate the clinical therapeutic
benefit of LB-100 in one or more cancers for which more effective
treatments are urgently needed. We are concentrating on small cell
lung cancer and advanced soft tissue sarcomas. Many investigators
of which Shuhaibar and colleagues are among the most recent have
used LB-100 in pre-clinical studies that have revealed targeting of
PP2A function appears to have a multitude of potential applications
to serious human diseases in addition to cancer.”
About Lixte
Biotechnology Holdings, Inc.
Lixte Biotechnology Holdings,
Inc. (Nasdaq:LIXT) is a clinical-stage pharmaceutical company
dedicated to discovering drugs for more effective treatments for
many forms of cancer and other serious common diseases. A major
driver of cancer is defects in the switches that turn the
biochemical pathways in cells on and off. Most cancer research over
the past 30 years has focused on the “on” switches because the
“off” switches, especially the master “off” switch protein
phosphatase (PP2A), were believed to cause intolerable toxicity in
patients. Lixte has achieved a breakthrough with its novel,
first-in-class lead compound, PP2A inhibitor LB-100, by
demonstrating that it is readily tolerated in cancer patients at
doses associated with anti-cancer activity. This innovative
approach encourages cancer cells, damaged by chemotherapy or other
cancer therapies, to continue to replicate before repairing the
damage, leading to the more efficient death and elimination of
those cells from the body. Lixte has partnered with top
medical institutions and leading academic research centers to
advance the clinical development of its compounds. The LB-100
compound, of which there are no competitors known to Lixte, is
being tested in three clinical cancer treatment studies with others
in planning. Additional information can be obtained at the
Company’s website at www.lixte.com.
Forward-Looking Statements
This announcement contains certain
forward-looking statements within the meaning of Section 27A of the
Securities Act of 1933, and Section 21E of the Securities Exchange
Act of 1934. For example, statements regarding the Company's
financial position, business strategy and other plans and
objectives for future operations, and assumptions and predictions
about future product demand, supply, manufacturing, costs,
marketing and pricing factors are all forward-looking statements.
These statements are generally accompanied by words such as
"intend," anticipate," "believe," "estimate," "potential(ly),"
"continue," "forecast," "predict," "plan," "may," "will," "could,"
"would," "should," "expect" or the negative of such terms or other
comparable terminology. The Company believes that the assumptions
and expectations reflected in such forward-looking statements are
reasonable, based on information available to it on the date
hereof, but the Company cannot provide assurances that these
assumptions and expectations will prove to have been correct or
that the Company will take any action that the Company may
presently be planning. However, these forward-looking statements
are inherently subject to known and unknown risks and
uncertainties. Actual results or experience may differ materially
from those expected or anticipated in the forward-looking
statements. Factors that could cause or contribute to such
differences include, but are not limited to, regulatory policies,
available cash, research results, competition from other similar
businesses, and market and general economic factors. This
discussion should be read in conjunction with the Company's filings
with the United States Securities and Exchange Commission
at sec.gov/edgar.shtml.
Lixte
Contact:info@lixte.comGeneral Phone: (631)
830-7092Investor Phone: (888) 289-5533
Grafico Azioni Lixte Biotechnology (NASDAQ:LIXT)
Storico
Da Giu 2024 a Lug 2024
Grafico Azioni Lixte Biotechnology (NASDAQ:LIXT)
Storico
Da Lug 2023 a Lug 2024